Aventis Behring Zemaira approval
This article was originally published in Pharmaceutical Approvals Monthly
Aventis Behring plans to launch its alpha-1 proteinase inhibitor Zemaira before the end of September. FDA approved the biologic July 8 for use as chronic augmentation and maintenance therapy in individuals with A1-PI deficiency and clinical evidence of emphysema. Aventis will use 50 internal sales reps, but is looking to bolster promotions with an external distribution partner. The fast-track product was submitted in January and received a priority review. Zemaira is the third AI-PI to clear FDA, following Bayer's Prolastin and Baxter's Aralast...
You may also be interested in...
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
Look! Up in the sky! It’s a bird! It’s a plane! It’s … a COVID-19 test from Quest Diagnostics.
New directors at 4D Pharma, Neurogene And Zogenix.